Pharmacokinetic Effects of Coadministration of Lersivirine with Raltegravir or Maraviroc in Healthy Subjects

Lersivirine (UK-453,061) is a new nonnucleoside reverse transcriptase inhibitor currently being developed as a treatment for human immunodeficiency virus type 1 infection. Lersivirine shows potent activity against wild-type and clinically relevant drug-resistant strains. Previous studies have demons...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Vourvahis, Manoli, Langdon, Grant, LaBadie, Robert R., Layton, Gary, Ndongo, Marie-Noella, Banerjee, Subhashis, Davis, John
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2012
Assuntos:
Antiviral Agents
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3264271/
https://ncbi.nlm.nih.gov/pubmed/22123705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00572-11
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares